MA55903A - Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t - Google Patents

Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t

Info

Publication number
MA55903A
MA55903A MA055903A MA55903A MA55903A MA 55903 A MA55903 A MA 55903A MA 055903 A MA055903 A MA 055903A MA 55903 A MA55903 A MA 55903A MA 55903 A MA55903 A MA 55903A
Authority
MA
Morocco
Prior art keywords
lymphocyte
modulating
materials
methods
mediated immunity
Prior art date
Application number
MA055903A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Iqbal S Grewal
Sanjaya Singh
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55903A publication Critical patent/MA55903A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055903A 2019-05-08 2020-05-07 Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t MA55903A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844966P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08

Publications (1)

Publication Number Publication Date
MA55903A true MA55903A (fr) 2022-03-16

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055903A MA55903A (fr) 2019-05-08 2020-05-07 Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t

Country Status (21)

Country Link
US (2) US11667712B2 (fr)
EP (1) EP3965818A4 (fr)
JP (1) JP2022533538A (fr)
KR (1) KR20220017892A (fr)
CN (1) CN113966231A (fr)
AU (1) AU2020267504A1 (fr)
BR (1) BR112021022089A2 (fr)
CA (1) CA3139508A1 (fr)
CL (1) CL2021002905A1 (fr)
CO (1) CO2021015998A2 (fr)
CR (1) CR20210548A (fr)
DO (1) DOP2021000229A (fr)
EC (1) ECSP21087921A (fr)
IL (1) IL287817A (fr)
JO (1) JOP20210297A1 (fr)
MA (1) MA55903A (fr)
MX (1) MX2021013532A (fr)
PE (1) PE20220763A1 (fr)
SG (1) SG11202112021QA (fr)
TW (1) TW202108618A (fr)
WO (1) WO2020227457A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
EP4298125A1 (fr) 2021-02-26 2024-01-03 LAVA Therapeutics N.V. Anticorps se liant à des récepteurs des lymphocytes t cd123 et gamma-delta

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2467738A1 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
WO2009018386A1 (fr) 2007-07-31 2009-02-05 Medimmune, Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2347038A4 (fr) 2008-10-14 2013-06-12 Janssen Biotech Inc Procédés d humanisation et de maturation d affinité d anticorps
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
BR112013002831A2 (pt) 2010-08-05 2016-11-01 Anaptysbio Inc anticorpos direcionados contra a il-17
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP6339015B2 (ja) * 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
US9718893B2 (en) * 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
EP3060059A4 (fr) * 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Cellules t gamma delta polyclonales pour l'immunothérapie
JP6617138B2 (ja) * 2014-04-10 2019-12-11 ラヴァ・セラピューティクス・ベー・フェー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
AU2017388346A1 (en) 2016-12-26 2019-07-11 Kagoshima University Antibody capable of binding to myelin oligodendrocyte glycoprotein
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
EP3743081A4 (fr) 2018-01-23 2021-12-01 New York University Anticorps spécifiques de la chaîne delta 1 du récepteur des lymphocytes t
WO2021173896A1 (fr) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Matériels et méthodes de modulation d'une réponse immunitaire
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CA3199767A1 (fr) 2020-10-28 2022-05-05 Janssen Biotech, Inc. Compositions et procedes de modulation de l'immunite a mediation par la chaine gamma delta

Also Published As

Publication number Publication date
JOP20210297A1 (ar) 2023-01-30
US20240150464A1 (en) 2024-05-09
CR20210548A (es) 2022-02-11
KR20220017892A (ko) 2022-02-14
BR112021022089A2 (pt) 2022-02-08
CO2021015998A2 (es) 2021-12-10
MX2021013532A (es) 2022-02-11
CA3139508A1 (fr) 2020-11-12
SG11202112021QA (en) 2021-11-29
CL2021002905A1 (es) 2022-06-17
CN113966231A (zh) 2022-01-21
WO2020227457A1 (fr) 2020-11-12
DOP2021000229A (es) 2022-07-31
JP2022533538A (ja) 2022-07-25
AU2020267504A1 (en) 2021-12-02
US20210032338A1 (en) 2021-02-04
TW202108618A (zh) 2021-03-01
ECSP21087921A (es) 2022-01-31
EP3965818A1 (fr) 2022-03-16
EP3965818A4 (fr) 2023-05-31
IL287817A (en) 2022-01-01
US11667712B2 (en) 2023-06-06
PE20220763A1 (es) 2022-05-16

Similar Documents

Publication Publication Date Title
MA54952A (fr) Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
MA52198A (fr) Systèmes et méthodes pour l'administration retardée de médicament
MA55903A (fr) Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA45035A (fr) Combinaisons d'arnm codant pour des polypeptides de modulation immunitaire et leurs utilisations
MA46643A (fr) Méthodes et compositions pour le mappage d'arn
MA51993A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur
IL278924A (en) Antibodies specific to GUCY2C and their uses
MA53827A (fr) Modulateurs de l'alpha -1 antitrypsine
MA53822A (fr) Protéines de fusion fc hétérodimères d'il -12
IL276459A (en) Variable regions of an antibody that targets the NKG2D receptor
EP3695852A4 (fr) Anticorps anti-mésothéline et conjugué anticorps-médicament associé
SG11202101675UA (en) Anti-bcma single domain antibodies and application thereof
MA52154A (fr) Composition pharmaceutique pour l'anémie
MA50369A (fr) Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament
FR3006566B1 (fr) Applicateur pour appliquer un produit sur les cils et/ou les sourcils
EP3762774A4 (fr) Modulateur de phase optique et modulateur optique
IL277842A (en) Chimeric proteins of growth differentiation factor 15
MA53218A (fr) Antagonistes de l'intégrine
MA53924A (fr) Modulateurs de l'expression d'apol1
MA51788A (fr) Substances et méthodes pour traiter des hémoglobinopathies
FR3006565B1 (fr) Applicateur pour appliquer un produit sur les cils et/ou les sourcils
MA52545A (fr) Anticorps pour radionucléides chélatés
MA53831A (fr) Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques
MA43181A (fr) Méthodes et compositions comprenant des facteurs de croissances, de la chondroïtine et de la glucosamine pour la régénération d'un disque dégénératif